ESMO22 - Neoadjuvante immunotherapie bij dMMR-coloncarcinoom

In deze podcast bespreekt internist-oncoloog Koos van der Hoeven met internist-oncoloog Myriam Chalabi, werkzaam in het Antoni van Leeuwenhoek te Amsterdam de NICHE-2-studie; neoadjuvante immunotherapie bij dMMR-coloncarcinoom. Chalabi presenteerde de studie tijdens een Presidential Symposium op het ESMO Congress 2022. Aan bod komen onder andere waarom de studie is uitgevoerd, hoe en de belangrijkste resultaten.

Episode metadata supplied by the publisher feed · Published Sep 16, 2022

Embed this episode

Attribution link and audio player

Ready to play

ESMO22 - Neoadjuvante immunotherapie bij dMMR-coloncarcinoom

0:00 17:32

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Oncologie.nu?

This episode is 17 minutes long.

When was this Oncologie.nu episode published?

This episode was published on September 16, 2022.

Can I download this Oncologie.nu episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!